Vimpat Approved for Primary Generalized Tonic-Clonic Seizures
The FDA also approved Vimpat Injection for use in pediatric patients 4 years of age and older.
Seizure Disorders
Room Temperature Stable Fosphenytoin Gets FDA Approval
The product is a ready-to-dilute, room temperature stable formulation of fosphenytoin for IV injection, which allows for point-of-care storage.
Neurologic Complications Seen in Hospitalized COVID-19 Patients
Neurologic disorders tied to increased risk for in-hospital mortality.
FDA Issues Complete Response Letter for Libervant
Libervant is a buccally administered soluble film of diazepam used to treat acute uncontrolled seizures in patients with refractory epilepsy on stable AED regimens.
FDA Requires Boxed Warning Update for Benzodiazepines
Benzodiazepines are widely used to treat a variety of conditions including anxiety disorders, insomnia and seizures.
Epidiolex Approved for Tuberous Sclerosis Complex-Associated Seizures
Epidiolex is a pharmaceutical formulation of highly purified cannabidiol.
MPR Weekly Dose Podcast Episode 41
This week on the Pod: The FDA issues guidance for COVID-19 vaccine development; Accuracy in COVID-19 antibody testing; How statins may improve outcomes for hospitalized COVID-19 patients; and in non-COVID-related news there’s a new drug approvals in breast cancer and Dravet syndome.
New Treatment Option for Dravet Syndrome Approved
The FDA has approved Fintepla® (fenfluramine; Zogenix) oral solution for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older.
FDA Approves DBS Neurostimulation System With Brain Signal Tracking
The FDA has approved the Percept™ PC Deep Brain Stimulation (DBS) system (Medtronic) with BrainSense™ technology for neurological disorders.
New Drug Product: Xcopri
This slideshow shows drug information for Xcopri. Click here for the complete Xcopri monograph. For a downloadable version of this slideshow, click here.
